Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03560934 · ClinicalTrials.gov registry record · Early Phase 1

Tetrahydrocannabinol (THC) and Sleep

A Early Phase 1 study, sponsored by Oregon Health and Science University.

Completed
Registry status
Early Phase 1
Development phase
18
Enrollment target

NCT03560934 is a Early Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03560934, a Early Phase 1 study, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
Early Phase 1
Development phase
18 participants
Enrollment target

Study Summary

The investigators will test the effects of 10-60mg dronabinol (oral THC) on sleep in non-frequent and frequent cannabis users.

Interventions

  • DRUG Dronabinol

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2018-09-01
Est. Completion 2025-12-31
Phase Early Phase 1

What the Registry Record Tells You About NCT03560934

The ClinicalTrials.gov registry entry for NCT03560934 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Dronabinol is the first listed.

NCT03560934 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03560934 about?

NCT03560934 is a clinical study titled "Tetrahydrocannabinol (THC) and Sleep". The investigators will test the effects of 10-60mg dronabinol (oral THC) on sleep in non-frequent and frequent cannabis users.

What is the current status of trial NCT03560934?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2018-09-01. Estimated completion is 2025-12-31.

What interventions are being tested in trial NCT03560934?

The interventions under investigation include: Dronabinol (DRUG).

Who is sponsoring clinical trial NCT03560934?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.